From public T-cell engager evidence to the next experiment
Public PopPK and efficacy reconstruction, Bayesian CRS sensitivity, and hypothetical measurement value and sampling design.
Daiki Kumakura
I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
I study biological dynamics using mathematical models and data analysis, with an interest in pharmacometrics and systems biology.
Recent writing
用量比較試験は用量選択をどこまで支持するか：sotorasib 960 mgと240 mgの群別データから
無作為化用量比較の公開群別データから、便益と害の重みを変えたときの判定領域を示す。重症毒性の差は頑健だが、奏効率とOSの差は不確かで、結論は害の定義に依存する。臨床用量の推奨は行わない。
Do two immune-biology scores improve response prediction across urothelial cancer cohorts?
Fixed Teff and stromal features evaluated across public urothelial cancer cohorts, with discrimination, calibration, missingness and transport limits.